Small caps round-up: Mears, ITM, Matra...
9th Jun 2010 07:26
Social housing group Mears will repeat last month's interim management statement at its AGM today, highlighting continued strong trading across the business. "Mears is well positioned to benefit from an active contract bidding market and remains confident in the prospects for the future growth of t
Read moreSmall caps round-up: Healthcare Enterprise, Dragon Oil, Phoenix IT
7th Apr 2010 11:49
Shares in Healthcare Enterprise jumped after the healthcare group reported that one of the companies in which it has shares has been given formal approval to sell an artificial insemination device in the US. Reproductive Sciences, which is 27% owned by Healthcare Enterprise, said the US Food and Dr
Read moreSanderson chairman buys nearly 25% of company
1st Feb 2010 16:26
Christopher Winn, the executive chairman of enterprise software provider Sanderson Group, has bought nearly all of private equity firm Alchemy's stake in the company. Alchemy was involved in the original management buy out of Sanderson in December 1999, which was split into three companies includ
Read moreBroker tips: ITM Power, BG Group, M&S
12th Aug 2009 12:34
Shares in ITM Power have rallied sharply lately, but broker Panmure Gordon sees room for much more growth and lifts its rating on the developer of alternative fuels to 'buy' from 'hold'. The firm has had a few technical difficulties, but these have been resolved and a deal with a blue-chip customer
Read moreBroker snap: Panumure upgrades ITM Power
12th Aug 2009 12:02
Shares in ITM Power have rallied sharply lately, but broker Panmure Gordon sees room for much more growth and lifts its rating on the developer of alternative fuels to 'buy' from 'hold'. The firm has had a few technical difficulties, but these have been resolved and a deal with a blue-chip customer
Read moreSmall caps round-up: BTG, Arbuthnot, United Carpets...
29th Jul 2009 11:02
BTG shares rallied as its partner AstraZeneca confirmed its intention to progress severe sepsis treatment CytoFab into a Phase IIb study. This decision follows the successful completion by AstraZeneca of a Phase IIa study of CytoFab in 70 patients with severe sepsis. Arbuthnot Banking made a "satis
Read moreSmall caps round-up: Quadnetics, Innovation Group, Oxonica ...
7th Jul 2009 09:20
CCTV supplier Quadnetics said as anticipated trading in the second half year was substantially stronger than the first half. The group said underlying results for the full year will be in line with current market expectations. Year end cash balances were ahead of expectations. Innovation Group, w
Read more